

Roberta Zanardini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1305795/publications.pdf>

Version: 2024-02-01

45
papers

2,418
citations

185998

28
h-index

233125

45
g-index

45
all docs

45
docs citations

45
times ranked

4288
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2022, 16, 758182.	1.4	4
2	Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Cells</i> , 2022, 11, 462.	1.8	7
3	Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer's Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 667369.	1.8	18
4	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13633.	1.8	8
5	Childhood trauma and glucose metabolism in patients with first-episode psychosis. <i>Psychoneuroendocrinology</i> , 2020, 113, 104536.	1.3	15
6	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in first-episode psychosis. <i>Microbial Biotechnology</i> , 2020, 14, 507-511.	0.9	15
7	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1443.	1.8	60
8	Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment. <i>Mechanisms of Ageing and Development</i> , 2020, 186, 111210.	2.2	23
9	Immune and metabolic alterations in first episode psychosis (FEP) patients. <i>Brain, Behavior, and Immunity</i> , 2018, 70, 315-324.	2.0	31
10	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1477-1483.	1.2	15
11	Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1053-1060.	1.2	6
12	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 610-618.	1.3	12
13	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 753-760.	1.2	26
14	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 10.	1.7	16
15	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. <i>Neuropsychobiology</i> , 2016, 74, 15-21.	0.9	8
16	Glucose metabolism alterations in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2015, 184, 293-298.	2.0	34
17	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 461-466.	2.2	34
18	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 173-177.	2.8	40

#	ARTICLE	IF	CITATIONS
19	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. <i>BioTechniques</i> , 2014, 57, 111-114.	0.8	34
20	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. <i>Journal of Neurology</i> , 2013, 260, 640-650.	1.8	50
21	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013, 9, 677-686.	0.4	51
22	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	137
23	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. <i>Alzheimer's and Dementia</i> , 2012, 8, 520-527.	0.4	32
24	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. <i>Trials</i> , 2012, 13, 73.	0.7	47
25	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1322-1325.	2.5	73
26	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, no-no.	1.4	36
27	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 323-329.	1.8	54
28	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 103.	1.0	82
29	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. <i>Journal of Neurology</i> , 2010, 257, 2004-2014.	1.8	44
30	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. <i>BMC Neuroscience</i> , 2010, 11, 16.	0.8	16
31	Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: A case-control study. <i>Journal of Affective Disorders</i> , 2010, 122, 174-178.	2.0	76
32	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 763-773.	1.3	363
33	VEGF serum levels in depressed patients during SSRI antidepressant treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 146-149.	2.5	61
34	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. <i>Neuroscience Letters</i> , 2008, 437, 130-134.	1.0	79
35	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 79, 712-715.	0.9	12
36	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. <i>European Neuropsychopharmacology</i> , 2006, 16, 620-624.	0.3	149

#	ARTICLE	IF	CITATIONS
37	The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. <i>Neuroscience Letters</i> , 2006, 406, 133-137.	1.0	58
38	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. <i>Journal of Affective Disorders</i> , 2006, 91, 83-86.	2.0	137
39	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 132B, 1-4.	1.1	39
40	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 356, 119-122.	1.0	49
41	Association between IL-1 β -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. <i>Journal of Psychiatric Research</i> , 2003, 37, 457-462.	1.5	52
42	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 480-484.	0.7	81
43	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. <i>Psychiatry Research</i> , 2001, 104, 1-9.	1.7	40
44	Association between α G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. <i>Molecular Psychiatry</i> , 2001, 6, 79-82.	4.1	172
45	β -Thalassaemia as a result of a novel splice donor site mutation of the β -globin gene. <i>British Journal of Haematology</i> , 2000, 110, 694-698.	1.2	22